Upgrade to SI Premium - Free Trial

Summit Therapeutics (SMMT)

18.68 +1.13 (6.44%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Form 8-K Summit Therapeutics Inc. For: Sep 13 September 14, 2026 8:38 AM - SEC Filing Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer September 13, 2026 7:47 PM - StreetInsider Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study September 13, 2026 7:00 AM - BizWire Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy September 9, 2026 6:45 AM - StreetInsider UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT) September 8, 2026 9:12 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) September 3, 2026 6:57 AM - StreetInsider Summit Therapeutics plc (SMMT) Reiterated at Overweight by Cantor Fitzgerald September 1, 2026 6:54 AM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Aug 25 August 26, 2026 9:17 AM - SEC Filing Guggenheim Reiterates Buy Rating on Summit Therapeutics plc (SMMT) August 26, 2026 7:09 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) August 26, 2026 6:40 AM - StreetInsider Akeso's ivonescimab beats durvalumab in biliary tract cancer trial August 25, 2026 6:39 PM - StreetInsider Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria August 25, 2026 6:00 PM - BizWire Summit Therapeutics publishes HARMONi Phase III lung cancer trial data August 25, 2026 7:02 AM - StreetInsider Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology August 25, 2026 7:00 AM - BizWire Bernstein SocGen Group Upgrades Summit Therapeutics plc (SMMT) to Market Perform August 25, 2026 2:25 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) August 19, 2026 6:49 AM - StreetInsider China approves ivonescimab plus chemo for squamous NSCLC August 12, 2026 9:22 AM - StreetInsider Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer August 12, 2026 9:22 AM - BizWire Leerink Upgrades Summit Therapeutics plc (SMMT) to Market Perform August 12, 2026 6:34 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) August 6, 2026 6:55 AM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Aug 05 August 5, 2026 7:32 AM - SEC Filing Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer August 5, 2026 7:00 AM - BizWire Summit Therapeutics (SMMT) spreader of 10K contracts of January 10 and 25 calls trade July 27, 2026 6:32 AM - StreetInsider Summit Therapeutics plc (SMMT) PT Lowered to $38 at Stifel, But 'Fundamental Conviction Intact' July 24, 2026 7:38 AM - StreetInsider Summit Therapeutics plc (SMMT) PT Lowered to $38 at Guggenheim July 24, 2026 6:59 AM - StreetInsider Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald After Q2 Results July 24, 2026 6:53 AM - StreetInsider Summit Therapeutics (SMMT) Reports In-Line Q2 EPS July 23, 2026 5:42 PM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Jul 23 July 23, 2026 4:35 PM - SEC Filing Form 424B5 Summit Therapeutics Inc. July 23, 2026 4:34 PM - SEC Filing Summit Therapeutics: substantial doubt about our ability to continue as a going concern July 23, 2026 4:25 PM - StreetInsider Form 10-Q Summit Therapeutics Inc. For: Jun 30 July 23, 2026 4:09 PM - SEC Filing Form 8-K Summit Therapeutics Inc. For: Jul 23 July 23, 2026 4:08 PM - SEC Filing Summit Therapeutics posts Q2 loss, reports ivonescimab trial data July 23, 2026 4:06 PM - StreetInsider Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 July 23, 2026 4:05 PM - BizWire H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) July 23, 2026 7:10 AM - StreetInsider Arcus and Summit team up to test kidney cancer drug combo July 22, 2026 4:30 PM - StreetInsider Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer July 22, 2026 4:30 PM - BizWire Form 8-K Summit Therapeutics Inc. For: Jul 22 July 22, 2026 7:11 AM - SEC Filing Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial July 22, 2026 6:30 AM - StreetInsider Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study July 22, 2026 6:30 AM - BizWire Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 July 16, 2026 8:00 AM - BizWire H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) July 16, 2026 6:48 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) July 15, 2026 7:37 AM - StreetInsider Summit Therapeutics sells antibiotic asset ridinilazole for up to $105M July 14, 2026 7:00 AM - StreetInsider Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. July 14, 2026 7:00 AM - BizWire The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution June 25, 2026 11:40 AM - StreetInsider Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group June 22, 2026 6:32 AM - StreetInsider Full Article List